scholarly journals Response to First-Line Antiretroviral Therapy Among PLHIV from a High-Risk, Low-Prevalence Setting

2019 ◽  
Vol 18 ◽  
pp. 232595821986732
Author(s):  
Shahria Mohammad Rashed Ul Islam ◽  
Munira Jahan ◽  
Afzalun Nessa ◽  
Shahina Tabassum
Keyword(s):  
Antiretroviral Therapy ◽  
T Lymphocyte ◽  
Lymphocyte Count ◽  
Study Groups ◽  
People Living With Hiv ◽  
First Line ◽  
Cd8 T Lymphocyte ◽  
The Mean ◽  
Low Prevalence ◽  
Living With Hiv

The study reports the response of first-line antiretroviral therapy (ART) by assessing CD4 and CD8 T-lymphocyte and viral load (VL) among Bangladeshi people living with HIV (PLHIV). This observational approach was conducted on 100 PLHIVs, grouped into therapy naive (n = 33), therapy initiators with CD4 T-cell count of <350 cells/µL (n = 33), and therapy receivers for >1 year prior to the study period (n = 34). Therapy initiators who continued the study (n = 20) were followed up after 12 and 24 weeks of therapy initiation. The CD4 and CD8 T-lymphocyte count estimation and (VL) were quantified. The mean CD4 T-lymphocyte count was significantly reduced among the therapy initiators in comparison to therapy naive and therapy receivers. Similar findings were observed for CD8 T-lymphocyte count among the study groups. The mean HIV-1 RNA VL among therapy initiators showed a significant decrease after 12 and 24 weeks, and 85% patients in this group obtained undetectable VL status indicating the good therapeutic outcome.

scholarly journals First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study

2011 ◽  
Vol 8 (1) ◽  
pp. 33 ◽  
Author(s):  
Eric Pefura Yone ◽  
Awa Betyoumin ◽  
André Kengne ◽  
François Kaze Folefack ◽  
Jeanne Ngogang
Keyword(s):  
Antiretroviral Therapy ◽  
Cross Sectional Study ◽  
People Living With Hiv ◽  
Sectional Study ◽  
First Line ◽  
Cross Sectional ◽  
Living With Hiv ◽  
Hiv 1

scholarly journals Assessment of HIV disease progression before and after initiation of anti­retroviral therapy by CD4 & CD8 T-lymphocyte count and viral load assay

2016 ◽  
Vol 6 (1) ◽  
pp. 48
Author(s):  
Sahina Tabassum ◽  
S.M. Rashed-ul Islam ◽  
Afzalun Nessa ◽  
Munira Jahan ◽  
Saif Ullah Munshi
Keyword(s):  
Viral Load ◽  
T Lymphocyte ◽  
Lymphocyte Count ◽  
Published Data ◽  
Art Initiation ◽  
Cd8 T Lymphocyte ◽  
Virological Outcome ◽  
Before And After ◽  
Study Population ◽  
The Mean

<p><strong>Backgrounds:</strong> As there is no published data regarding the response to Anti-retroviral therapy (ART) among HIV patients from Bangladesh. The present study was designed to determine the immunological and virological responses of HIV infected Bangladeshi adults starting ART. Objectives: To monitor the changes of CD4 and CD8 T-lymphocyte count and Viral load (VL) before and after three and six months of starting ART.</p><p><strong>Methods:</strong> 20 symptomatic HIV infected patients with CD4 T-lymphocyte count of &lt;350 cells/µ] of blood were initiated ART.CD4 and CDS T-lymphocyte counts were estimated by Flowcytometer and VL was dete1mined by real-time PCR technique.</p><p><strong>Results:</strong> The mean CD4 T-lymphocyte count among the sn1dy patients were 177±127 cells/µl before initiation of ART. After ART initiation, their mean CD4 count increased significantly to 368±181 and 452±183 cellshll after three and six months respectively (P&lt;0.0001).The mean CDS T-lymphocyte counts were 901±650 cells/µ! before initiation of ART, which increased to I 085±393 and 1121±372 cells/µl after three and six months respectively after ART initiation (P&gt;0.05). Before ART initiation, the mean VL was 5.25±1.19 log10 (copies/ml) among the study population which became undetectable in 15 (75%) patients after three months of ART and in another 2 (10%) patients after 6 months of ART initiation.</p><p><strong>Conclusion:</strong> Our study concluded that, ART is effective in slowing the progression of HIV infection to AIDS with good immunological and virological outcome among the ART initiators.</p>

scholarly journals Factors associated to modification of first-line antiretroviral therapy due to adverse events in people living with HIV/AIDS

2020 ◽  
Vol 24 (1) ◽  
pp. 65-72 ◽  
Author(s):  
Larissa Negromonte Azevedo ◽  
Ricardo Arraes de Alencar Ximenes ◽  
Polyana Monteiro ◽  
Ulisses Ramos Montarroyos ◽  
Demócrito de Barros Miranda-Filho
Keyword(s):  
Antiretroviral Therapy ◽  
Adverse Events ◽  
People Living With Hiv ◽  
First Line ◽  
Factors Associated ◽  
Living With Hiv ◽  
Hiv Aids

scholarly journals Driving Force of Covid-19 Among People Living With HIV/AIDS in Wuhan, China

2020 ◽  
Author(s):  
Wei Guo ◽  
Fangzhao Ming ◽  
Yu Dong ◽  
Qian Zhang ◽  
Lian Liu ◽  
...  
Keyword(s):  
T Lymphocyte ◽  
Lymphocyte Count ◽  
Driving Force ◽  
Driving Forces ◽  
People Living With Hiv ◽  
Hiv Diagnosis ◽  
Hiv Viral Load ◽  
Increased Risk ◽  
Living With Hiv ◽  
Hiv Aids

Abstract Background: Even people living with HIV/AIDS (PLWHA) were considered to be at increased risk of SARS-CoV-2 infection, the driving force among this group of individuals is still not clear. Methods: We investigated 1,701 PLWHA through a telephone interview and found 11 COVID-19 patients in four districts of Wuhan, China. The demographic features and major clinical characteristics of these patients were retrieved from the information management systems for COVID-19 patients of four districts’ CDC. Statistical analysis was performed to find out the driving force of COVID-19 among PLWHA.Results: The incidence proportion of COVID-19 in PLWHA is 0.6% (95% CI: 0.2% - 1.0%), which is comparable to the overall population incidence rate in Wuhan city (0.6%). Nine out of the 11 COVID-19/AIDS patients had relatively high CD4+ T lymphocyte count (>200/μl) and undetectable HIV viral load (＜20 copies/ml), and ten of them were on antiretroviral therapy. PLWHA who were old, had low CD4+ T lymphocyte count, infected HIV through homosexual activity, and had been diagnosed for HIV for a long time, were more likely to develop COVID-19.Conclusions: PLWHA has comparable COVID-19 morbidity rates as the general population, and older age, low CD4 count, long length since HIV diagnosis, and treatment-naive were potential driving forces of COVID-19 occurrence among PLWHA. Strategies in preventing SARS-CoV-2 infection among PLWHA with worse immune responses are needed. Article Summary Line: As COVID-19 continues to spread around the world, people living with HIV/AIDS (PLWHA) are also at risk of infection with SARS-CoV-2. We investigated the factors associated with SARS-CoV-2 infection among PLWHA in Wuhan, China.

scholarly journals Hepatitis B infection in people living with HIV who initiate antiretroviral therapy in Zimbabwe

2020 ◽  
Vol 10 (3) ◽  
pp. 97-103
Author(s):  
T. P. Goverwa-Sibanda ◽  
C. Mupanguri ◽  
C. Timire ◽  
A. D. Harries ◽  
S. Ngwenya ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Hepatitis B ◽  
Opportunistic Infections ◽  
Hepatitis B Surface Antigen ◽  
Prevalence Ratio ◽  
Diagnosis And Treatment ◽  
People Living With Hiv ◽  
First Line ◽  
Cross Sectional ◽  
Living With Hiv

Setting: There is little information about the diagnosis and treatment of hepatitis B virus (HBV) infection in people living with HIV (PLHIV) in Zimbabwe despite recommendations that tenofovir (TDF) + lamivudine (3TC) is the most effective nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) backbone of antiretroviral therapy (ART) in those with dual infection.Objective: To determine 1) numbers screened for hepatitis B surface antigen (HBsAg); 2) numbers diagnosed HBsAg-positive along with baseline characteristics; and 3) NRTI backbones used among PLHIV initiating first-line ART at Mpilo Opportunistic Infections Clinic, Bulawayo, Zimbabwe, between October 2017 and April 2019.Design: This was a cross-sectional study using routinely collected data.Results: Of the 422 PLHIV initiating first-line ART (median age 34 years, IQR 25–43), 361 (85%) were screened for HBV, with 10% being HBsAg-positive. HBsAg positivity was significantly associated with anaemia (adjusted prevalence ratio [aPR] 2.3, 95%CI 1.1–4.7) and elevated ala-nine transaminase levels (aPR 2.9, 95%CI 1.5–5.8). Of 38 PLHIV who were diagnosed HBsAg-positive, 30 (79%) were started on ART based on tenofovir (TDF) and lamivudine (3TC), seven were given abacavir (ABC) + 3TC-based ART and one was given zido vudine (ZDV) + 3TC-based ART.Conclusion: In PLHIV, HBV screening worked well, the prevalence of HIV-HBV co-infection was high and most patients received appropriate treatment for both conditions. Recommendations to improve screening, diagnosis and treatment of HIV-HBV co-infection are discussed.

scholarly journals Role of CD4+ and CD8+ T Lymphocyte in the Onset of Stroke in People Living with HIV in Pointe-Noire

2022 ◽  
Vol 12 (01) ◽  
pp. 1-7
Author(s):  
Prince Eliot Galieni Sounga Bandzouzi ◽  
Ghislain Armel Mpandzou ◽  
Josué Euberma Diatewa ◽  
Dina Happia Motoula-Latou ◽  
Charles Godefroy Koubemba ◽  
...  
Keyword(s):  
T Lymphocyte ◽  
People Living With Hiv ◽  
Cd8 T Lymphocyte ◽  
Pointe Noire ◽  
Living With Hiv

scholarly journals A STUDY OF PEOPLE LIVING WITH HIV-AIDS [PLHA] ON FIRST LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY [HAART] WITH IMMUNOLOGICAL FAILURE

2016 ◽  
Vol 5 (56) ◽  
pp. 3872-3876
Author(s):  
Natarajan Kandasamy ◽  
Vijayanand Radhakrishnan ◽  
Ashokkumar Subramanian ◽  
Ravichandran Narayanan ◽  
Mohamed Kalifa Adbul Muthalif ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
People Living With Hiv ◽  
First Line ◽  
Immunological Failure ◽  
Highly Active ◽  
Living With Hiv ◽  
Hiv Aids

Assessment of atherosclerotic cardiovascular disease risks between people living with HIV receiving first-line and second-line antiretroviral therapy in a resource-limited setting

2021 ◽  
Vol 32 (5) ◽  
pp. 421-426
Author(s):  
Jaruwan Tiarukkitsagul ◽  
Somnuek Sungkanuparph
Keyword(s):  
Cardiovascular Disease ◽  
People Living With Hiv ◽  
Atherosclerotic Cardiovascular Disease ◽  
Second Line ◽  
First Line ◽  
Resource Limited ◽  
Ascvd Risk ◽  
The Mean ◽  
Living With Hiv ◽  
Limited Setting

Cardiovascular disease has become an important health problem in people living with HIV (PLHIV) who receive antiretroviral therapy (ART). Atherosclerotic cardiovascular disease (ASCVD) risk score is a non-invasive tool to estimate the 10-year risk for ASCVD. A cross-sectional study was conducted among PLHIV receiving ART in a resource-limited setting, in order to assess the 10-year ASCVD risk between PLHIV receiving first-line and second-line ART. Of 460 participants with a mean age of 51.2 years, 262 (57.0%) were men. The mean duration of HIV infection was 14.7 years and the mean CD4 cell count was 509 cells/μL. Of all, 345 participants were receiving first-line ART and 115 were receiving second-line ART. The median 10-year ASCVD risk was 3.0% and 5.1% in the first-line and second-line ART groups, respectively ( p = 0.029). The prevalence of a high 10-year ASCVD risk (≥20%) was significantly higher in the second-line ART group (3.5% vs 0.9%, p = 0.048). In multivariate analysis, receiving second-line ART was significantly associated with intermediate to high 10-year ASCVD risk (OR = 2.952; 95% CI, 1.656–6.997; p = 0.015). Atherosclerotic cardiovascular disease risk should be assessed in PLHIV, particularly those who receive second-line ART.

Risk Factor Of Substitution ARV First Line People Living With HIV/AIDS In General Hospital Buleleng Bali

2020 ◽  
Vol 9 (1) ◽  
pp. 190-197
Author(s):  
Luh Putu Desy Puspaningrat ◽  
Gusti Putu Candra ◽  
Putu Dian Prima Kusuma Dewi ◽  
I Made Sundayana ◽  
Indrie Lutfiana
Keyword(s):  
Risk Factor ◽  
General Hospital ◽  
Medical Records ◽  
Secondary Data ◽  
District General Hospital ◽  
People Living With Hiv ◽  
First Line ◽  
The Past ◽  
Factor Substitution ◽  
Living With Hiv

Substitution is still a threat to the failure of ARV therapy so that no matter how small it must be noted and monitored in ARV therapy. The aims  was analysis risk factor substitution ARV first line in therapy ARV. This study was an analytic longitudinal study with retrospective secondary data analysis in a cohort of patients receiving ARV therapy at the District General Hospital of Buleleng District for the period of 2006-2015 and secondary data from medical records of PLHA patients receiving ART.  Result in this study that the percentage of first-line ARV substitution events is 9.88% (119/1204) who received ARV therapy for the past 11 years. Risk factors that increase the risk of substitution in ARV therapy patients are zidovudine (aOR 4.29 CI 1.31 -2.65 p 0.01), nevirapine (aOR1.86 CI 2.15 - 8.59 p 0.01) and functional working status (aOR 1.46 CI 1.13 - 1.98 p 0.01). 

Sign in / Sign up

Export Citation Format

Share Document